AOD-9604 / CJC-1295 / Ipamorelin

This blend combines AOD-9604 with two growth-hormone-axis research peptides. The mixture itself has no established evidence base and must be evaluated separately from its constituents.

Potential component-level pathways include experimental metabolic signaling, GHRH-receptor activation, and ghrelin-receptor activation.

Blend-level evidence is unestablished.

Blend, No established blend evidence

Component studies do not demonstrate compatibility, stability, pharmacology, or safety of the combined material.

Potential endocrine, metabolic, cardiovascular, immunogenicity, impurity, and interaction risks are not established.

No FDA-approved drug product; requires exact identity and blend-specific analytical data.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.